Author Correction: Benralizumab Phase 3 Trial Data Updated in Nature Medicine
Nature Medicine published an author correction on May 5, 2026, for a randomized, placebo-controlled phase 3 trial investigating benralizumab versus placebo for hypereosinophilic syndrome (HES). The original article, released on March 31, 2026, contained specific data errors in Table 1 and Supplementary Table 2. The correction addresses an incorrect PROMIS Fatigue median value for the total population, which was updated from 51.1 to 55.1. Additionally, several values in Supplementary Table 2 were rectified: the median eosinophil count for the benralizumab group changed from 1,070.0 to 1,085.0, and the total population median shifted from 1,120.0 to 1,100.0. The percentage of patients receiving prior omalizumab therapy in the benralizumab arm was also corrected from 1.5% to 3.0%. These updates have been applied to both the HTML and PDF versions of the study. The research, involving authors from global institutions including AstraZeneca and various university hospitals, focuses on immunology and medical research. This correction ensures the accuracy of clinical data regarding the efficacy and baseline characteristics of benralizumab treatment for HES patients.
Wire timeline
Author Correction: Benralizumab Phase 3 Trial Data Updated in Nature Medicine
Nature Medicine published an author correction on May 5, 2026, for a randomized, placebo-controlled phase 3 trial investigating benralizumab versus placebo for hypereosinophilic syndrome (HES). The original article, released on March 31, 2026, contained specific data errors in Table 1 and Supplementary Table 2. The correction addresses an incorrect PROMIS Fatigue median value for the total population, which was updated from 51.1 to 55.1. Additionally, several values in Supplementary Table 2 were rectified: the median eosinophil count for the benralizumab group changed from 1,070.0 to 1,085.0, and the total population median shifted from 1,120.0 to 1,100.0. The percentage of patients receiving prior omalizumab therapy in the benralizumab arm was also corrected from 1.5% to 3.0%. These updates have been applied to both the HTML and PDF versions of the study. The research, involving authors from global institutions including AstraZeneca and various university hospitals, focuses on immunology and medical research. This correction ensures the accuracy of clinical data regarding the efficacy and baseline characteristics of benralizumab treatment for HES patients.
Nature Medicine